IN THE SPOTLIGHT

Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer

Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer

Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer

Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer

Antonio Passaro: COCOON study meets primary endpoint

Antonio Passaro: COCOON study meets primary endpoint

EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians

EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians

Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach

Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach

Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective

Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings